ClinicalTrials.gg

Program

dapagliflozin

Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.

Furthest: phase 4, since Jun 2, 2014131 company-led studies, 13 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca10910 open or runningphase 4since Jun 2, 2014Sep 9, 2005Dec 10, 2026phase 2 · NCT07222917
LG Chem60 open or runningphase 3since Feb 2, 2020May 24, 2018none ahead
Boryung Pharmaceutical32 open or runningphase 1since May 26, 2022May 26, 2022none ahead
Dong-A ST20 open or runningphase 3since Apr 20, 2020Dec 5, 2018none ahead
Hansoh Pharmaceutical Group20 open or runningphase 1since Apr 30, 2021Apr 30, 2021none ahead
autotelicbio10 open or runningphase 1since Apr 20, 2021Apr 20, 2021none ahead
Daewoong Pharmaceutical10 open or runningphase 3since Nov 12, 2020Nov 12, 2020none ahead
Dexa Medica Group10 open or runningno phasesince Nov 7, 2023Nov 7, 2023none ahead
dong-wha-pharmaceutical-co-ltd10 open or runningphase 1since May 4, 2022May 4, 2022none ahead
George Clinical Pty10 open or runningphase 4since Nov 3, 2020Nov 3, 2020none ahead
Hamad Medical10 open or runningphase 3since Jul 22, 2018Jul 22, 2018none ahead
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair11 open or runningphase 3since Jun 16, 2025Jun 16, 2025none ahead
Novartis10 open or runningphase 2since May 21, 2021May 21, 2021none ahead
thpharm-corp10 open or runningphase 1since Sep 8, 2023Sep 8, 2023none ahead
  • Named in AstraZeneca’s own pipeline as zibotentan/dapagliflozin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: fortrea, parexel, ground-zero-pharmaceuticals, pt-equilab-international, Bristol-Myers Squibb, q2-solutions, pra-health-sciences, covance and antaros-medical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Mar 15, 2016.

  1. Nov 5, 2024Phase 3 study in Heart FailureAstraZeneca · NCT06677060 · 11,300 planned · United States, Argentina, Australia and more
  2. Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06742723 · 5,000 planned · United States, Argentina, Australia and more
  3. Apr 17, 2025Phase 2 study in Kidney DiseasesAstraZeneca · NCT06942910 · 224 enrolled · Russia
  4. May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyAstraZeneca · NCT06979388 · 14 enrolled · United Kingdom
  5. Jun 16, 2025Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair's first study: phase 3 study in Diabetes Mellitus, Type 2New to Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair · NCT07033585 · 600 enrolled · United States
  6. Jul 16, 20252 phase 1 studies in Diabetes MellitusBoryung Pharmaceutical · NCT07083401, NCT07083388
  7. Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
  8. Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
  9. Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
  10. Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
  11. Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicAstraZeneca · NCT07404137 · 26 enrolled · United States
  12. May 29, 2026Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT07624305 · 2,800 planned · United States, Argentina, Austria and more
  13. Jun 18, 20262 phase 3 studies in Diabetes Mellitus, Type 2AstraZeneca · NCT07662109, NCT07662044
  14. Jul 13, 2026Phase 1 study in Renal InsufficiencyAstraZeneca · NCT07754331 · 10 enrolled · United States

Ahead

  1. Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917
  2. Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesAstraZeneca · NCT06087835
  3. May 31, 2027Primary completion: phase 4 study in Renal Insufficiency, ChronicAstraZeneca · NCT06610526
  4. Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873

TargetBeta

“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
ertugliflozinruleMerckphase 422
EnavogliflozinruleDaewoong Pharmaceuticalphase 325
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The newest 60 of 131 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07754331Renal Insufficiency · United States1CompletedAstraZenecaOct 6, 202610
NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3RecruitingAstraZenecaJul 5, 20282,000
NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more3RecruitingAstraZenecaJul 14, 2028800
NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more3RecruitingAstraZenecaJul 1, 20302,800
NCT07404137Renal Insufficiency, Chronic · United States1CompletedAstraZenecaApr 2, 202626
NCT07396844Fasting · Thailand1CompletedLG ChemJun 26, 202628
NCT07399470Healthy Volunteers · South Korea1CompletedLG ChemFeb 6, 202658
NCT07333742Fed Conditions · South Korea1CompletedLG ChemNov 27, 202550
NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more2Active, not recruitingAstraZenecaDec 10, 2026222
NCT07083401Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 5, 202640
NCT07083388Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 3, 202652
NCT07033585Diabetes Mellitus, Type 2 · United States3Active, not recruitingHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairOct 18, 2026600
NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom1CompletedAstraZenecaJul 12, 202514
NCT06942910Kidney Diseases · Russia2Active, not recruitingAstraZenecaSep 26, 2026224
NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingAstraZenecaDec 18, 20295,000
NCT06677060Heart Failure · United States, Argentina, Australia and more3RecruitingAstraZenecaDec 17, 202911,300
NCT06610526Renal Insufficiency, Chronic · China4Active, not recruitingAstraZenecaMay 31, 2027731
NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaFeb 24, 20282,554
NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more2CompletedAstraZenecaDec 11, 202473
NCT06127212Healthy · Indonesia–CompletedDexa Medica GroupMar 15, 202324
NCT06087835Kidney Diseases · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaFeb 18, 20271,835
NCT06063109Hypertension · South Korea1Completedthpharm-corpNov 9, 202351
NCT05516498Liver Cirrhosis · United States, Australia, Austria and more2TerminatedAstraZenecaMay 22, 2025205
NCT05411965Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedBoryung PharmaceuticalJul 3, 202248
NCT05403281Healthy Subjects · Korea, Republic of1Completeddong-wha-pharmaceutical-co-ltdDec 3, 202141
NCT05266404Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) · Germany1CompletedAstraZenecaMay 31, 202246
NCT04991571Renal Insufficiency, Chronic · United States1CompletedAstraZenecaOct 22, 202127
NCT04899349Breast Neoplasms · United States, Malaysia2TerminatedNovartisMay 10, 20232
NCT04881006Healthy Subjects · Canada1CompletedHansoh Pharmaceutical GroupDec 20, 202030
NCT04880993Healthy Subjects · Canada1CompletedHansoh Pharmaceutical GroupDec 24, 202030
NCT04856969Healthy Adult Volunteers · Korea, Republic of1CompletedautotelicbioMay 4, 202138
NCT04856007Healthy Volunteer · China1CompletedAstraZenecaJun 14, 202180
NCT04634500Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedDaewoong PharmaceuticalNov 3, 2021200
NCT04620590Diabetes Mellitus, Type 2 · United States, Canada4CompletedGeorge Clinical PtyMay 30, 202317
NCT04595370Heart Failure · United States, Belgium, Bulgaria and more2CompletedAstraZenecaSep 22, 2023153
NCT04564742Heart Failure · Sweden, United Kingdom3CompletedAstraZenecaJul 5, 20234,017
NCT04544319T2DM1UNKNOWNLG ChemMar 202144
NCT04445714Diabetes Mellitus, Type 2 · India4CompletedAstraZenecaMar 14, 2023196
NCT04356742Diabetes Mellitus, Type 2 · Korea, Republic of3CompletedDong-A STFeb 23, 2022198
NCT04255238Diabetes Mellitus, Type 23UNKNOWNLG ChemMay 30, 2022468
NCT03877237Heart Failure With Reduced Ejection Fraction (HFrEF) · United States, Brazil, Canada and more3CompletedAstraZenecaMar 7, 2020313
NCT03877224Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Argentina, Brazil and more3CompletedAstraZenecaJul 9, 2020504
NCT03766724Type2 Diabetes · Korea, Republic of1CompletedDong-A STJan 18, 201942
NCT03619213Heart Failure With Preserved Ejection Fraction · United States, Argentina, Belgium and more3CompletedAstraZenecaMar 27, 20226,263
NCT03658031Prediabetic State · Qatar3UNKNOWNHamad MedicalDec 31, 2020576
NCT03608358Diabetes Mellitus, Type 2 · Thailand, Vietnam3TerminatedAstraZenecaAug 4, 202041
NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of1UNKNOWNLG ChemAug 20, 201848
NCT03387683Diabetes Mellitus, Type 2 · Finland, Sweden4CompletedAstraZenecaMar 19, 201953
NCT03344341Diabetes Mellitus, Type 2 · China4TerminatedAstraZenecaMay 24, 2019304
NCT03338855Diabetes Mellitus, Type 2 · Netherlands4CompletedAstraZenecaNov 4, 201926
NCT03199053Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedAstraZenecaFeb 1, 2023256
NCT03169959Diabetes Mellitus, Type 2 · United States1CompletedAstraZenecaAug 3, 201785
NCT03138356Diabetes Mellitus, Type 2 · United Kingdom1CompletedAstraZenecaNov 28, 2017126
NCT03152084Diabetes Mellitus, Type 2 · Netherlands, Sweden4TerminatedAstraZenecaMar 20, 202024
NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil1CompletedAstraZenecaMay 22, 2018284
NCT03036150Renal Insufficiency, Chronic · United States, Argentina, Brazil and more3CompletedAstraZenecaJun 12, 20204,304
NCT03036124Heart Failure · United States, Argentina, Brazil and more3CompletedAstraZenecaJul 17, 20194,744
NCT02725593Diabetes Mellitus, Type 2 · United States, Hungary, Israel and more3CompletedAstraZenecaApr 6, 202072
NCT02719132Diabetes Mellitus, Type 24WithdrawnAstraZenecaNov 20170
NCT02722239Diabetes Mellitus, Type 2 · Russian Federation1CompletedAstraZenecaMay 5, 201640

How it is read

Names in the registry

  • “Dapagliflozin”, 90 entries
  • “dapagliflozin”, 18 entries
  • “Dapagliflozin 10 mg”, 6 entries
  • “Dapagliflozin 10mg”, 5 entries
  • “Dapagliflozin/metformin XR 10/1000mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.